NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

RecruitingPhase 4

Sponsor: Women and Infants Hospital of Rhode Island

Conditions: Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)

Interventions: Methenamine Hippurate, Typically prescribed oral antibiotic prophylaxis

Countries: United States

The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* 18 years of age or older
* undergoing intradetrusor BOTOX-A injections in the office setting for overactive bladder

Exclusion Criteria:

* cisgender male individuals
* neurogenic reasons for bladder symptoms (i.e. spinal cord injury, multiple sclerosis, etc.)
* known allergy and/or contraindication to methenamine hippurate
* currently already taking methenamine hippurate at the time of the procedure
* taking antibiotics for any reason on the day of their BOTOX-A procedure
* positive UTI at time of procedure (positive dip at time of procedure)
* history of bladder cancer
* history of pelvic radiation
* surgically altered detrusor muscle
* pre-procedural need for catheterization
* diagnosis of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
* pregnant or lactating individuals

Locations (1)

Providence, Rhode Island, United States